PsilodexMedication × psilocybin
Your list , 0 items
Medication class

Sleep medications and psilocybin.

28 records in this group. 2 have published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.

28Records
2With human data

Overview

Reviewed 2026-10-25

Sleep medications work in different ways. Z-drugs (zolpidem, eszopiclone, zaleplon) and benzodiazepines act on GABA-A, the brain's main inhibitory system; orexin blockers (suvorexant, lemborexant, daridorexant) block wake-promoting signals; sedating antihistamines (diphenhydramine, doxylamine, hydroxyzine) are also anticholinergic; and melatonin, ramelteon and tasimelteon act on melatonin receptors. Each adds sedation if still active during a session. Benzodiazepines combined with opioids can cause profound sedation, slowed breathing, coma and death (temazepam prescribing information).

Zolpidem's label carries a boxed warning for complex sleep behaviors such as sleepwalking and sleep-driving, including some resulting in serious injury or death, and describes hallucinations and withdrawal symptoms after abrupt stopping (Ambien prescribing information). Benzodiazepine labels carry a boxed warning that abrupt stopping or rapid dose reduction can cause withdrawal reactions, including seizures (temazepam prescribing information). Suvorexant's label describes sleep paralysis and hallucinations at sleep onset (Belsomra prescribing information).

Trazodone and mirtazapine block 5-HT2A, the serotonin receptor psilocybin acts on, and one systematic review anticipates that they reduce psychedelic effects (Halman 2024). With LSD, 28 of 32 people who had taken an SSRI or trazodone for more than 3 weeks, at antidepressant doses, reported a reduced or absent response in a retrospective questionnaire (Bonson 1996). No study has tested low bedtime doses. Zolpidem appears in one multi-drug case report, alongside phenelzine, nortriptyline, lithium and other drugs, in which psilocybin mushrooms produced no noticeable subjective effects; the report does not separate the drugs' effects (Barnett 2024).

Quetiapine, often used at low doses for sleep, is an antipsychotic; Colorado's rule names antipsychotic medications without distinguishing dose or reason for use, and quetiapine is covered on the antipsychotics page. Low-dose doxepin is a tricyclic; see the tricyclics page.

Psilodex presents published evidence and state psilocybin regulations for information only. It is not medical advice, a screening decision, or clearance to participate. Do not stop or change a medication without talking with the prescriber.

Also searched as sleeping pill · sleep aid · sleep medication · sleeping pills

01 What the evidence covers

Best evidence available per medication
2Case reports
Case reports or online surveys
26No psilocybin data
No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Each medication

A to Z
  • Acetaminophen–diphenhydramine · Tylenol PMEvidence: No psilocybin data

    Occasional headaches and minor aches and pains with accompanying sleeplessness

    It causes drowsiness and may cause confusion with psilocybin. The acetaminophen part has no known psilocybin interaction.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • CBD / CBNEvidence: No psilocybin data

    Anxiety; Chronic pain

    CBD may slow how the body clears psilocybin, more so at higher doses. Also, it can cause sleepiness; full-spectrum products contain trace THC.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Daridorexant · QuviviqEvidence: No psilocybin data

    Insomnia (trouble falling or staying asleep)

    Not studied with psilocybin; no linking mechanism is described. Also, it causes next-day sleepiness and can cause sleep paralysis or hallucinations at sleep-wake transitions.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Diphenhydramine · BenadrylEvidence: No psilocybin data

    Hay fever and upper respiratory allergy symptoms; Common cold symptoms (runny nose, sneezing)

    Its drowsiness and confusion may add to psilocybin's effects, though it has no meaningful serotonin effect. Also, it raises heart rate.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Doxepin · Sinequan, SilenorEvidence: No psilocybin data

    Depression; Anxiety

    In theory it blunts psilocybin, but related tricyclics strengthened LSD responses. Also, it sedates and affects heart rhythm; 3–6 mg acts mainly as an antihistamine.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Doxylamine · Unisom SleepTabsEvidence: No psilocybin data

    Trouble falling asleep (occasional sleeplessness); Nausea and vomiting of pregnancy (with pyridoxine, Rx)

    It is sedating and may cause confusion or delirium during psilocybin's altered state.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • EstazolamEvidence: No psilocybin data

    Insomnia (short-term)

    It adds sedation; untested with psilocybin (midazolam, the one studied, partly impaired memory of the session). Stopping it suddenly can cause seizures.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Eszopiclone · LunestaEvidence: No psilocybin data

    Insomnia

    It may add sedation if still active during a psilocybin session (not studied with psilocybin). Also, its label warns of complex sleep behaviors like sleep-driving.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Flunitrazepam · RohypnolEvidence: No psilocybin data

    Psychotropics

    It adds sedation; untested with psilocybin (midazolam, the one studied, partly impaired memory of the session). Stopping it suddenly can cause seizures.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • FlurazepamEvidence: No psilocybin data

    Insomnia

    It adds sedation; untested with psilocybin (midazolam, the one studied, partly impaired memory of the session). Stopping it suddenly can cause seizures.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Hydroxyzine · Vistaril, AtaraxEvidence: No psilocybin data

    Anxiety and tension; Itching from allergic skin conditions (hives, eczema, contact dermatitis)

    Its sleepiness and confusion may add to psilocybin's effects. Also, it can cause heart-rhythm (QT) effects, more so with other drugs that do this.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Ibuprofen–diphenhydramine · Advil PM, Motrin PMEvidence: No psilocybin data

    Occasional sleeplessness associated with minor aches and pains

    Its diphenhydramine causes drowsiness and may cause confusion under psilocybin. Also, regular ibuprofen use can raise blood pressure, as psilocybin briefly does.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Lemborexant · DayvigoEvidence: No psilocybin data

    Insomnia (trouble falling or staying asleep)

    Its sedation may add to psilocybin's effects; it has no serotonin effect. Also, its label describes hallucinations around sleep and more suicidal thoughts than placebo.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • MelatoninEvidence: No psilocybin data

    Jet lag; Delayed sleep timing (delayed sleep-wake phase disorder)

    Not studied with psilocybin; no linking mechanism is described. Also, it causes mild sedation.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Mirtazapine · RemeronEvidence: No psilocybin data

    Depression

    It blocks the receptor psilocybin works through, so it may weaken psilocybin's effects. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Naproxen–diphenhydramine · Aleve PMEvidence: No psilocybin data

    Occasional sleeplessness associated with minor aches and pains

    It causes drowsiness and may cause confusion with psilocybin; regular naproxen use can raise blood pressure, as psilocybin briefly does.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Quazepam · DoralEvidence: No psilocybin data

    Insomnia (trouble falling or staying asleep, or early waking)

    It adds sedation; untested with psilocybin (midazolam, the one studied, partly impaired memory of the session). Stopping it suddenly can cause seizures.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Quetiapine · Seroquel, Seroquel XREvidence: No psilocybin data

    Schizophrenia; Bipolar I disorder (manic episodes)

    It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Stopping it suddenly after regular use can cause withdrawal.

    CO: named in rule · OR: not mentioned in rule · NM: rules not final

  • Ramelteon · RozeremEvidence: No psilocybin data

    Insomnia (trouble falling asleep)

    Not studied with psilocybin; no linking mechanism is described.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Suvorexant · BelsomraEvidence: No psilocybin data

    Insomnia (trouble falling or staying asleep)

    Not studied with psilocybin; no linking mechanism is described; it is sedating. Also, its label notes sleep-onset hallucinations and complex sleep behaviors.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Tasimelteon · HetliozEvidence: No psilocybin data

    Non-24-hour sleep-wake disorder (adults); Nighttime sleep disturbances in Smith-Magenis syndrome (capsules age 16+; oral suspension ages 3-15)

    Not studied with psilocybin; no linking mechanism is described.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Temazepam · RestorilEvidence: No psilocybin data

    Insomnia (short-term)

    It adds sedation; untested with psilocybin (midazolam, the one studied, partly impaired memory of the session). Stopping it suddenly can cause seizures.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Trazodone · Desyrel, OleptroEvidence: Case reports

    Depression (major depressive disorder)

    In one case, nightly trazodone blocked psilocybin's psychedelic effects; it blocks the receptor psilocybin works through. Also, it can affect heart rhythm and blood pressure.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Triazolam · HalcionEvidence: No psilocybin data

    Insomnia (short-term, generally 7 to 10 days, adults)

    It adds sedation; untested with psilocybin (midazolam, the one studied, partly impaired memory of the session). Stopping it suddenly can cause seizures.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • ValerianEvidence: No psilocybin data

    Insomnia (sleep); Anxiety

    Valerian may add sedation to psilocybin (not studied). Stopping it suddenly after regular use may cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Zaleplon · SonataEvidence: No psilocybin data

    Insomnia (short-term, trouble falling asleep)

    It causes sedation and may make psilocybin feel weaker if still in the body. Also, its label reports hallucinations and worsening depression.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Zolpidem · Ambien, Ambien CR, IntermezzoEvidence: Case reports

    Insomnia with trouble falling asleep (short-term); Insomnia with trouble staying asleep (extended-release)

    In one case, psilocybin mushrooms with zolpidem, phenelzine and other drugs had no noticeable effect. Its sedation may overlap a session.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Zopiclone · Imovane, ZimovaneEvidence: No psilocybin data

    Psychotropics

    It causes sedation and may make psilocybin feel weaker if still in the body. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

03 Properties the records flag

Records with each flag
26Sedating or CNS depressant
16Withdrawal or rebound if stopped abruptly
15Psychiatric reactions
8Anticholinergic
5QT-prolonging
4Lowers blood pressure or causes orthostasis
3Blocks 5-HT2A (may blunt effects)
3Liver injury
3Lowers seizure threshold or carries seizure risk
3Serotonergic
2Dehydration or electrolyte risk
2Raises blood pressure or heart rate
1UGT inhibition (theoretical effect on psilocin levels)

Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.

04 State rules

Official text governs
COColorado · final · checked 2026-10-24

1 of 28 named by a provision.

Colorado rules 2.2(A)(6) and 2.2(A)(7) both address participants taking lithium or an antipsychotic, and the rule text does not state how the two fit together. The rule names “antipsychotic medications” and does not limit this by indication or dose. Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Under 2.2(A)(7), services may proceed only after a referral from a licensed provider (MD, DO, APN, PA or clinical facilitator), medical clearance from the participant's provider, or a consultation and risk review with a provider licensed to diagnose and treat the condition identified as a risk factor; the Facilitator documents the consultation, and where it identifies heightened risk, the rule requires a safety plan and written informed consent. A Clinical Facilitator who does not prescribe lithium or antipsychotics within their secondary license needs clearance from, or a consultation and risk review with, such a provider (2.5(A)(2)).

Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. 19 of the 28 medications in this group are psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.

OROregon · final · checked 2026-10-24

No provision names these medications or this group.

NMNew Mexico · pending · checked 2026-10-24

Rules not final; the proposed rules reviewed name no medication in this group.

05 Studies cited in this group

Records citing each
16Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18.
15Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976.
6Nicholas CR, Banks MI, Lennertz RC, et al. Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience. Transl Psychiatry 2024;14:372.
2Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: a scoping review. J Psychopharmacol 2025.
1Barnett BS, Koons CJ, Van den Eynde V, et al. Hypertensive emergency secondary to combining psilocybin mushrooms, extended release dextroamphetamine-amphetamine, and tranylcypromine. J Psychoactive Drugs 2024;57(3):297–303.
1Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 1996;14:425–436.
1Bonson KR, Murphy DL. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 1996;73:229–233.
1Falchi-Carvalho M, Palhano-Fontes F, Wießner I, et al. Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression. Neuropsychopharmacology 2025;50(6):895–903.
1Rosenblat JD, et al. Antidepressant effects of psilocybin in the absence of psychedelic effects. Am J Psychiatry 2023 (letter).
1Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 1998;9:3897–3902.

Related classes

Records reviewed 2026-09-30 to 2026-10-14. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z

AgreementPsilodex

Before you use Psilodex

Check each box to continue.

Your searches, your list and the medications you look up stay in this browser. We can't see them. Privacy · Emergency: 911 · Mental health crisis: call or text 988 · Poison Control: 1-800-222-1222

Terms version 2026-10-25